[Glia conditioned medium offers protection against the toxicity induced by 6-OH-dopamine in vivo].
BACKGROUND
Glia conditioned medium (GCM) is neurotrophic for dopaminergic (DA) neurons and protects against MPP+ toxicity in vitro. We present the data from the first study in vivo of the effects of GCM.


METHODS
The restorative effects were examined in rats with lesions produced by 6-hydroxy-dopamine (6-OH-DA) in the medial longitudinal fasciculus. At four weeks, animals with an apomorphine induced rotation rate above three per minute were randomised for infusion with GCM, defined medium (DM) or saline through a striatal cannula for two weeks. To investigate the protective effects of GCM, the animals received a striatal injection of GCM or vehicle at the same time as the lesion was induced by 6-OH-DA and were sacrificed three weeks later.


RESULTS
In the experiments on the restorative effect, the GCM infusion produced a significant increase in dopamine (DA) levels on the side with the lesion, in the limbic system (455.8 108.4 ng/g of tissue) and in the striatum (242.1 69.2 ng/g of tissue), as compared with the controls (110.8 36,4 and 108.4 22 ng/g). In the experiments on the protective effect, GCM induced higher levels of DA, 3,4-dihydroxyphenylacetic acid and 3 methoxytyramine (3-MT). In both models, the apomorphine induced rotation in animals with lesions caused by 6-OH-DA and treated with GCM was lower than that of the animals infused with DM or saline.


CONCLUSIONS
These experiments show that GCM has protective and restorative effects in an experimental model of Parkinson's disease.
Servicio de Neurología, Fundación Jiménez Díaz, Madrid, España. ufissdemencies@mutuaterrassa.es
A
A
Rojo
M A
MA
Mena-Gómez
A
A
Blázquez
M J
MJ
Casarejos
A
A
Fontán-Barreiro
J G
JG
de Yébenes
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects / Q000473:pathology; D001923:Brain Chemistry; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D004195:Disease Models, Animal; D018491:Dopamine Agonists / Q000494:pharmacology; D008297:Male; D009457:Neuroglia / Q000166:cytology / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity*; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D017077:Culture Media, Conditioned; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D016627:Oxidopamine; D001058:Apomorphine